Options Brief: Vivus (VVUS)

VVUS – Vivus, Inc. – The biopharmaceutical company attracted a number of bearish options investors in the first half of the trading day with the price of its shares lower by 1.45% to $9.54 as of 12:50 pm (ET). The bearish strategies employed on Vivus today are perhaps the work of investors bracing for share price erosion if the firm’s obesity drug, Qnexa, fails to garner approval from the Food and Drug Administration. The FDA is slated to release a preliminary report of its findings on July 13, 2010, ahead of its final decision scheduled for October 28, 2010. One investor purchased a ratio put spread in the July contract, which will yield significant profits if shares of the biopharmaceutical company fall ahead of July expiration. The trader is perhaps hedging the possibility of a less-than stellar preliminary report in July, which would likely send VVUS shares reeling. The options strategist purchased 2,500 puts at the July $9.0 strike at an average premium of $2.42 each, and sold 5,000 puts at the lower July $5.0 strike for a premium of $0.45 apiece. The net cost of the bearish play amounts to $1.52 per contract, thus positioning the investor to make money if Vivus’s shares decline 21.6% from the current price to breach the average breakeven point on the spread at $7.48 by July expiration day. The trader walks away with maximum potential profits of $2.48 per contract if VVUS shares plummet 58% to settle at $4.00 at expiration. Another pessimist initiated a longer-term bearish bet on VVUS by purchasing a 2,000-lot plain-vanilla debit put spread at the September $9.0/$4.0 strikes at a net cost of $2.50 per contract. The transaction yields maximum potential profits of $2.50 per contract if shares fall 58% to trade at or below $4.00 by expiration day in September. Options implied volatility on Vivus is up 7.2% to 263.98% as of 1:05 pm (ET).

About Andrew Wilkinson 1023 Articles

Affiliation: Interactive Brokers

Andrew Wilkinson is the senior market analyst at Interactive Brokers Group, where he provides daily commentary and analysis on U.S. equity options trading throughout the trading day. Andrew provides webinars designed to explain option-related trading scenarios covering futures, fixed income, forex and equities.

Interactive Brokers: Interactive Brokers offers direct market access to around 80 electronic global markets from a single account. Successful traders and investors understand that superior technology and lower trading costs can result in greater returns. For 32 years we have been building direct access trading technology that delivers real advantages to professionals worldwide. With consolidated equity capital of US $4.4 billion, IB and its affiliates exceed 1,000,000 trades per day. In addition, our prudent and conservative risk policies make Interactive Brokers a safe haven for your money. Discover some of the reasons why IB, the largest independent US broker/dealer, is the professional traders' and investors' choice.

Visit: Interactive Brokers

2 Comments on Options Brief: Vivus (VVUS)

  1. I don't think the stock will drop by that much before July expiration. The stock is only going to go up…… just look at the call/put ratio. It indicates positive momentum and bullish outlook on the stock. IT IS A BUY.

    • Also, their drug Avanfil for ED has shown excellent results in recent tests. It will be released in a few months & I believe also that this is a BUY.

Leave a Reply

Your email address will not be published.


*